RANDALL SATO: Open Payments
NPI 1619604022 · HONOLULU, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$394 in 9 payments from 5 companies in 2025. Trend: 2023 $96 · 2024 $306 · 2025 $394
Food & beverage: $394
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $151 |
| Neurocrine BioSciences, Inc. | 1 | $128 |
| Teva Pharmaceuticals USA, Inc. | 2 | $52 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $38 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
Products named: ABILIFY ASIMTUFII, INGREZZA, AUSTEDO XR, CAPLYTA, INVEGA SUSTENNA, ABILIFY MAINTENA.
Industry payments across HI — which companies pay providers there.
